– Treasury Website
Amgen Announces FDA Approval Of RIABNI
New Indication for Amgen's Fifth FDA-approved Biosimilar
Now Approved to Treat All Available Rituxan® Indications
THOUSAND OAKS, Calif., June 6, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today